Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.36 |
| ▸ | BRD2 | P25440 | 5/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 2/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885639 | 0.82 | CDK2 (0.35) | BRD4BRD2CREBBPCTSABRD3 | |
| SCHEMBL1883829 | 0.80 | IDH1 (0.35) | BRD4BRD2CREBBPATMCTSA | |
| SCHEMBL14768191 | 0.80 | IDH1 (0.35) | BRD4BRD2CREBBPATMCTSA | |
| SCHEMBL1882135 | 0.80 | PIK3CD (0.40) | BRD4BRD2CREBBPATMCTSA | |
| SCHEMBL1882140 | 0.80 | PIK3CD (0.40) | BRD4BRD2CREBBPATMCTSA | |
| SCHEMBL1883325 | 0.79 | ATM (0.42) | ATMNPC1POLBRAB9APIK3CD | |
| SCHEMBL1881117 | 0.79 | ATM (0.48) | ATMRAB9APIK3CD | |
| SCHEMBL14768026 | 0.77 | HTT (0.38) | BRD4BRD2CREBBPATMCTSA | |
| SCHEMBL1881740 | 0.75 | ADORA2A (0.36) | ATMPOLBPIK3CD | |
| SCHEMBL1875421 | 0.75 | CYP2A6 (0.40) | ATMNPC1POLBRAB9APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231641-B1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-06-01 | — | — | EP | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | BRD4 487/4885BRD2 965/4885CREBBP 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.